This clinical update could positively influence AstraZeneca’s stock performance by bolstering investor confidence in the company’s innovative pipeline. The success of GC012F (AZD0120) could also ...

This update could impact AstraZeneca’s stock performance positively if the results show promising safety and efficacy, potentially boosting investor confidence. In a competitive pharmaceutical ...

We will be totally self-sufficient for the supply of medicines to American patients.” AstraZeneca CEO Pascal Soriot on the ...

Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

New long-term results for Tagrisso in EGFR-mutated non-small cell lung cancer showcase a precision approach the company has honed for decades.

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

AstraZeneca AZN-Q -1.14% on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, ...

AstraZeneca’s chief executive has said the drugmaker is a “very American company” amid growing speculation that it will ditch ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer ...